Table of Contents Author Guidelines Submit a Manuscript
Gastroenterology Research and Practice
Volume 2012, Article ID 879676, 9 pages
http://dx.doi.org/10.1155/2012/879676
Research Article

In Situ Absorption in Rat Intestinal Tract of Solid Dispersion of Annonaceous Acetogenins

Institute of Medicinal Plant Development, Chinese Academy of Medical Sciences, Beijing 100193, China

Received 18 July 2011; Revised 23 October 2011; Accepted 11 November 2011

Academic Editor: D. Fan

Copyright © 2011 Yun-Jie Dang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. F. Q. Alali, X. X. Liu, and J. L. McLaughlin, “Annonaceous acetogenins: recent progress,” Journal of Natural Products, vol. 62, no. 3, pp. 504–540, 1999. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Bermejo, B. Figadère, M. C. Zafra-Polo, I. Barrachina, E. Estornell, and D. Cortes, “Acetogenins from annonaceae: recent progress in isolation, synthesis and mechanisms of action,” Natural Product Reports, vol. 22, no. 2, pp. 269–303, 2005. View at Publisher · View at Google Scholar · View at Scopus
  3. J. L. McLaughlin, “Paw paw and cancer: annonaceous acetogenins from discovery to commercial products,” Journal of Natural Products, vol. 71, no. 7, pp. 1311–1321, 2008. View at Publisher · View at Google Scholar · View at Scopus
  4. Q. Ye, K. He, N. H. Oberlies et al., “Longimicins A-D: novel bioactive acetogenins from Asimina longifolia (annonaceae) and structure-activity relationships of asimicin type of annonaceous acetogenins,” Journal of Medicinal Chemistry, vol. 39, no. 9, pp. 1790–1796, 1996. View at Publisher · View at Google Scholar · View at Scopus
  5. N. H. Oberlies, C. J. Chang, and J. L. McLaughlin, “Structure-activity relationships of diverse annonaceous acetogenins against multidrug resistant human mammary adenocarcinoma (MCF-7/Adr) cells,” Journal of Medicinal Chemistry, vol. 40, no. 13, pp. 2102–2106, 1997. View at Publisher · View at Google Scholar · View at Scopus
  6. S. Yang, J. Yu, and L. Xu, “Chemical constituents of annonaceae plants and their antitumor activities,” Acta Academiae Medicinae Sinicae, vol. 22, no. 4, pp. 376–382, 2000. View at Google Scholar
  7. J. R. Tormo, T. Gallardo, R. Aragón, D. Cortes, and E. Estornell, “Specific interactions of monotetrahydrofuranic annonaceous acetogenins as inhibitors of mitochondrial complex I,” Chemico-Biological Interactions, vol. 122, no. 3, pp. 171–183, 1999. View at Publisher · View at Google Scholar
  8. T. Gallardo, J. Saez, H. Granados et al., “10-oximeguanacone, the first nitrogenated acetogenin derivative found to be a potent inhibitor of mitochondrial complex I,” Journal of Natural Products, vol. 61, no. 8, pp. 1001–1005, 1998. View at Publisher · View at Google Scholar · View at Scopus
  9. S. Derbré, S. Gil, M. Taverna et al., “Highly cytotoxic and neurotoxic acetogenins of the Annonaceae: new putative biological targets of squamocin detected by activity-based protein profiling,” Bioorganic and Medicinal Chemistry Letters, vol. 18, no. 21, pp. 5741–5744, 2008. View at Publisher · View at Google Scholar · View at Scopus
  10. A. Cavé, B. Figadère, A. Laurens, and D. Cortes, “Acetogenins from Annonaceae,” Fortschritte der Chemie organischer Naturstoffe, vol. 70, pp. 81–288, 1997. View at Google Scholar
  11. M. C. Zafra-Polo, B. Figadère, T. Gallardo, J. R. Tormo, and D. Cortes, “Natural acetogenins from annonaceae, synthesis and mechanisms of action,” Phytochemistry, vol. 48, no. 7, pp. 1087–1117, 1998. View at Publisher · View at Google Scholar · View at Scopus
  12. L. Zeng, Q. Ye, N. H. Oberlies et al., “Recent advances in annonaceous acetogenins,” Natural Product Reports, vol. 13, no. 4, pp. 275–306, 1996. View at Google Scholar · View at Scopus
  13. K. Kuwabara, M. Takada, J. Iwata et al., “Design syntheses and mitochondrial complex I inhibitory activity of novel acetogenin mimics,” European Journal of Biochemistry, vol. 267, no. 9, pp. 2538–2546, 2000. View at Publisher · View at Google Scholar · View at Scopus
  14. A. Lannuzel, P. P. Michel, G. U. Höglinger et al., “The mitochondrial complex I inhibitor annonacin is toxic to mesencephalic dopaminergic neurons by impairment of energy metabolism,” Neuroscience, vol. 121, no. 2, pp. 287–296, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. M. Escobar-Khondiker, M. Höllerhage, M. P. Muriel et al., “Annonacin, a natural mitochondrial complex I inhibitor, causes tau pathology in cultured neurons,” Journal of Neuroscience, vol. 27, no. 29, pp. 7827–7837, 2007. View at Publisher · View at Google Scholar · View at Scopus
  16. S. S. F. Yuan, H. L. Chang, H. W. Chen et al., “Selective cytotoxicity of squamocin on T24 bladder cancer cells at the S-phase via a Bax-, Bad-, and caspase-3-related pathways,” Life Sciences, vol. 78, no. 8, pp. 869–874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  17. M. Degli Esposti, A. Ghelli, M. Ratta, D. Cortes, and E. Estornell, “Natural substances (acetogenins) from the family Annonaceae are powerful inhibitors of mitochondrial NADH dehydrogenase (Complex I),” Biochemical Journal, vol. 301, no. 1, pp. 161–167, 1994. View at Google Scholar · View at Scopus
  18. S. S. F. Yuan, H. L. Chang, H. W. Chen et al., “Selective cytotoxicity of squamocin on T24 bladder cancer cells at the S-phase via a Bax-, Bad-, and caspase-3-related pathways,” Life Sciences, vol. 78, no. 8, pp. 869–874, 2006. View at Publisher · View at Google Scholar · View at Scopus
  19. M. C. Lu, S. H. Yang, S. L. Hwang et al., “Induction of G2/M phase arrest by squamocin in chronic myeloid leukemia (K562) cells,” Life Sciences, vol. 78, no. 20, pp. 2378–2383, 2006. View at Publisher · View at Google Scholar · View at Scopus
  20. C. C. Liaw, T. Y. Wu, F. R. Chang, and Y. C. Wu, “Historic perspectives on Annonaceous acetogenins from the chemical bench to preclinical trials,” Planta Medica, vol. 76, no. 13, pp. 1390–1404, 2010. View at Publisher · View at Google Scholar · View at Scopus
  21. W. L. Chiou and S. Riegelman, “Pharmaceutical applications of solid dispersion systems,” Journal of Pharmaceutical Sciences, vol. 60, no. 9, pp. 1281–1302, 1971. View at Google Scholar · View at Scopus
  22. J. L. Ford, “The current status of solid dispersions,” Pharmaceutica Acta Helvetiae, vol. 61, no. 3, pp. 69–88, 1986. View at Google Scholar · View at Scopus
  23. C. Leuner and J. Dressman, “Improving drug solubility for oral delivery using solid dispersions,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 47–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  24. K. Sekiguchi and N. Obi, “Studies on absorption of eutectic mixtures. I. A comparison of the behaviour of eutectic mixture of sulfathiazole and that of ordinary sulfathiazole in man,” Chemical & Pharmaceutical Bulletin, vol. 9, pp. 866–872, 1961. View at Google Scholar
  25. M. Moneghini, I. Kikic, D. Voinovich, B. Perissutti, and J. Filipović-Grčić, “Processing of carbamazepine—PEG 4000 solid dispersions with supercritical carbon dioxide: preparation, characterisation, and in vitro dissolution,” International Journal of Pharmaceutics, vol. 222, no. 1, pp. 129–138, 2001. View at Publisher · View at Google Scholar
  26. C. Leuner and J. Dressman, “Improving drug solubility for oral delivery using solid dispersions,” European Journal of Pharmaceutics and Biopharmaceutics, vol. 50, no. 1, pp. 47–60, 2000. View at Publisher · View at Google Scholar · View at Scopus
  27. S. Okonogi, T. Oguchi, E. Yonemochi, S. Puttipipatkhachorn, and K. Yamamoto, “Improved dissolution of ofloxacin via solid dispersion,” International Journal of Pharmaceutics, vol. 156, no. 2, pp. 175–180, 1997. View at Publisher · View at Google Scholar · View at Scopus
  28. T. Vasconcelos, B. Sarmento, and P. Costa, “Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs,” Drug Discovery Today, vol. 12, no. 23-24, pp. 1068–1075, 2007. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Lennernäs, “Human intestinal permeability,” Journal of Pharmaceutical Sciences, vol. 87, no. 4, pp. 403–410, 1998. View at Publisher · View at Google Scholar · View at Scopus
  30. N. Mori, T. Yokooji, Y. Kamio, and T. Murakami, “Characterization of intestinal absorption of mizoribine mediated by concentrative nucleoside transporters in rats,” European Journal of Pharmacology, vol. 586, no. 1–3, pp. 52–58, 2008. View at Publisher · View at Google Scholar · View at Scopus
  31. J. S. Kim, S. Mitchell, P. Kijek, Y. Tsume, J. Hilfinger, and G. L. Amidon, “The suitability of an in situ perfusion model for permeability determinations: utility for BCS class I biowaiver requests,” Molecular Pharmaceutics, vol. 3, no. 6, pp. 686–694, 2006. View at Publisher · View at Google Scholar · View at Scopus
  32. H. Li, X. Zhao, Y. Ma, G. Zhai, L. Li, and H. Lou, “Enhancement of gastrointestinal absorption of quercetin by solid lipid nanoparticles,” Journal of Controlled Release, vol. 133, no. 3, pp. 238–244, 2009. View at Publisher · View at Google Scholar · View at Scopus
  33. A. Dahan and G. L. Amidon, “Segmental dependent transport of low permeability compounds along the small intestine due to P-glycoprotein: the role of efflux transport in the oral absorption of BCS class III drugs,” Molecular Pharmaceutics, vol. 6, no. 1, pp. 19–28, 2009. View at Publisher · View at Google Scholar · View at Scopus
  34. I. Soria and C. L. Zimmerman, “Intestinal absorption of (-)-carbovir in the rat,” Pharmaceutical Research, vol. 11, no. 2, pp. 267–271, 1994. View at Publisher · View at Google Scholar · View at Scopus
  35. A. H. Eriksson, M. V. S. Varma, E. J. Perkins, and C. L. Zimmerman, “The intestinal absorption of a prodrug of the mGlu2/3 receptor agonist LY354740 is mediated by PEPT1: in situ rat intestinal perfusion studies,” Journal of Pharmaceutical Sciences, vol. 99, no. 3, pp. 1574–1581, 2010. View at Publisher · View at Google Scholar · View at Scopus
  36. A. Streubel, J. Siepmann, and R. Bodmeier, “Drug delivery to the upper small intestine window using gastroretentive technologies,” Current Opinion in Pharmacology, vol. 6, no. 5, pp. 501–508, 2006. View at Publisher · View at Google Scholar · View at Scopus
  37. N. Tanaka, K. Imai, K. Okimoto et al., “Development of novel sustained-release system, disintegration-controlled matrix tablet (DCMT) with solid dispersion granules of nilvadipine (II): in vivo evaluation,” Journal of Controlled Release, vol. 112, no. 1, pp. 51–56, 2006. View at Publisher · View at Google Scholar · View at Scopus
  38. T. Vasconcelos, B. Sarmento, and P. Costa, “Solid dispersions as strategy to improve oral bioavailability of poor water soluble drugs,” Drug Discovery Today, vol. 12, no. 23-24, pp. 1068–1075, 2007. View at Publisher · View at Google Scholar · View at Scopus